Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

Adaia Albasanz-Puig 1,2,†, Xavier Durà-Miralles 1,†, Júlia Laporte-Amargós 1, Isabel Ruiz-Camps 2,4, Pedro Puerta-Alcalde 5, Edson Abdala 6, Chiara Oltolini 2, Murat Akova 8, José Miguel Montejo 9, Malgorzata Mikulska 10, Pilar Martín-Dávila 2,11, Fabián Herrera 12, Oriol Gasch 13, Lubos Drgona 14, Hugo Manuel Paz Morales 15, Anne-Sophie Brunel 16, Estefania García 17, Burcu Isler 18, Winfried V. Kern 19, Pilar Retamar-Gentili 2,20, José María Aguado 2,21, Milagros Montero 22, Souha S. Kanj 23, Oguz R. Sipahi 24, Sebnem Calik 25, Ignacio Márquez-Gómez 26, Jorge I. Marín 27, Marisa Z. R. Gomes 28,*, Philipp Hemmati 29, Rafael Araos 30, Maddalena Peghin 31, José Luis del Pozo 32,*, Lucrezia Yáñez 33, Robert Tilley 34, Adriana Manzur 35, Andres Novo 36, Natália Pallarés 37, Alba Bergas 38,*, Jordi Carratalà 1,2,* and on behalf of the IRONIC Study Group †

1 Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain; adaia.albasanz@gmail.com (A.A.-P.); xavierduramiralles@gmail.com (X.D.-M.); jlaporte@iconcologia.net (J.L.-A.); albabergas@gmail.com (A.B.); cgudiol@iconcologia.net (C.G.)
2 Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), Instituto de Salud Carlos III, 28209 Madrid, Spain; iruiz@vhebron.net (I.R.-C.);
3 Hematology Department, Catalan Institute of Oncology (ICO)-Duran i Reynals Hospital, IDIBELL, 08907 Barcelona, Spain; amussetti@iconcologia.net
4 Infectious Diseases Department, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
5 Infectious Diseases Department, Hospital Clinic i Provincial, 08035 Barcelona, Spain; puerta@clinic.cat
6 Instituto del Cáncer del Estado de São Paulo, Faculty of Medicine, University of São Paulo, São Paulo 01246, Brazil; edafula@uol.com.br
7 Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; oliotini.chiar@irs.it
8 Department of Infectious Diseases, Hacettepe University School of Medicine, 06230 Ankara, Turkey; akova.murat@gmail.com
9 Infectious Diseases Department, Cruces University Hospital, 48903 Bilbao, Spain; josemiguel.montejobaranda@osakidetza.eus
10 Division of Infectious Diseases, Department of Health Sciences, University of Genoa (DISSAL) and Ospedale Policlinico San Martino, 16132 Genoa, Italy; m.mikulska@unige.it
11 Infectious Diseases Department, Ramon y Cajal Hospital, 28034 Madrid, Spain
12 Infectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires C1430EFA, Argentina; fabian1961@gmail.com
13 Infectious Diseases Department, Parc Taulí University Hospital, Sabadell, 08208 Barcelona, Spain; ogasch@tauli.cat
14 Oncomediatology Department, Comenius University and National Cancer Institute, 81499 Bratislava, Slovakia; lubos.drgona@gmail.com
15 Infectious Diseases Department, Hospital Erasto Gaertner, Curitiba 81520-060, Brazil; Moraleshmp@gmail.com
16 Infectious Diseases Department, Department of Medicine, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland; anne-sophie.brunel@chuv.ch
17 Haematology Department, Reina Sofia University Hospital-IMIBIC-UCO, 14004 Córdoba, Spain; estefania.garcia.spa@juntadeandalucia.es
18 Department of Infectious Diseases and Clinical Microbiology, Istanbul Education and Research Hospital, Istanbul 34669, Turkey; burcubayrak85@gmail.com
19 Division of Infectious Diseases, Department of Medicine II, University of Freiburg Medical Center and Faculty of Medicine, 79100 Freiburg, Germany; winfried.kern@uniklinik-freiburg.de
20 Unit of Infectious Diseases and Microbiology, University Hospital Virgen Macarena, Department of Medicine, Universidad de Sevilla, Institute of Biomedicine of Seville, Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, 41013 Seville, Spain
21 Infectious Diseases Unit, Instituto de Investigación Hospital “12 de Octubre” (i + 12), “12 de Octubre” University Hospital, School of Medicine, Universidad Complutense, 28041 Madrid, Spain

Received: 24 February 2022
Accepted: 21 March 2022
Published: 29 March 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Abstract: To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with *Pseudomonas aeruginosa* (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006–2018). The effect of appropriate empirical combination therapy, appropriate monotherapy and inappropriate empirical antibiotic therapy [IEAT] on 30-day case-fatality was assessed only in patients with PA bacteremic pneumonia. Among 1017 PA BSI episodes, pneumonia was the source of BSI in 294 (28.9%). Among those, 52 (17.7%) were caused by a multidrug-resistant (MDR) strain and 68 (23.1%) received IEAT, mainly when the infection was caused by an MDR strain [38/52 (73.1%) vs. 30/242 (12.4%); \( p < 0.001 \)]. The 30-day case-fatality rate was higher in patients with PA bacteremic pneumonia than in those with PA BSI from other sources (55.1% vs. 31.4%; \( p < 0.001 \)). IEAT was associated with increased 30-day case-fatality (aHR 1.44 [95%CI 1.01–2.03]; \( p = 0.042 \)), whereas the use of appropriate combination empirical treatment was independently associated with improved survival (aHR 0.46 [95%CI 0.27–0.78]; \( p = 0.004 \)). Appropriate empirical monotherapy was not associated with improved overall survival (aHR 1.25 [95%CI 0.76–2.05]; \( p = 0.39 \)). Combination antibiotic empirical therapy should be administered promptly in febrile neutropenic patients with suspected pneumonia as the source of infection.

Keywords: *Pseudomonas aeruginosa*; bloodstream infection; pneumonia; septic shock; neutropenia

1. Introduction

*Pseudomonas aeruginosa* (PA) bloodstream infection (BSI) remains one of the leading causes of death among neutropenic cancer patients [1,2]. The administration of inadequate initial empirical antibiotic treatment for PA BSI in this population has been associated with impaired outcomes [3–5]. Importantly, due to the worrisome increase in multidrug resistance among PA isolates, the rates of inadequate empirical antibiotic treatment are increasing with a detrimental impact on mortality [1,6].

Data from a few retrospective studies suggest that an initial combination empirical therapy with two active antipseudomonal antibiotics raises levels of appropriate treatment in patients with PA BSI, and consequently improves outcomes [4,7]. Nevertheless, the possible benefit of combined treatment over monotherapy is still a matter of vivid debate [8–11]. The issue is controversial because the mortality attributed to PA BSI might not be determined only by the appropriateness of the empirical antibiotic treatment, but also by the source of infection, the baseline characteristics of the infected host and the severity of the clinical presentation [12–14]. In this regard, bacterial pneumonia is common in febrile neutropenic patients, with a prevalence that ranges from 16% to 40% of cases [15]. More specifically, 31.5% of patients with acute leukemia [16] and 64% of allogeneic hematopoietic stem cell
transplant recipients will develop an episode of pneumonia [17], with unacceptably high case-fatality rates, particularly when compared with infections from other sources [18–20].

PA is one of the main causative agents of pneumonia in neutropenic cancer patients [21,22]. It frequently presents with BSI, septic shock and/or requires intensive care unit admission [20,23,24]. Even though the most recent Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines recommend an initial empirical therapy with two active antipseudomonal antibiotics for hospital-acquired pneumonia in patients at high risk for mortality and/or antimicrobial resistance [25], the true impact of this strategy in febrile neutropenic patients with PA pneumonia is still unknown. In fact, the currently available guidelines for the management of febrile neutropenia lack specific recommendations regarding the empirical treatment of pneumonia in neutropenic patients [26].

In this study, we assess the effect of combination antibiotic empirical therapy versus monotherapy on 30-day mortality in neutropenic cancer patients with PA bacteremic pneumonia.

2. Materials and Methods

2.1. Study Design and Setting

This study is part of the IRONIC project: a multicenter, international, retrospective cohort study conducted from 1 January 2006 to 31 May 2018 at 34 centers in 12 countries. The number of participating centers is provided in the Supplementary material. The number of patients recruited at each participating center has been reported elsewhere [27].

2.2. Ethics

The study was approved by the Institutional Review Board at Bellvitge University Hospital (local reference number PR408/17) and by the local Research Ethics Committees at the participating centers. It was conducted in accordance with the Declaration of Helsinki guidelines. The need for informed consent was waived by the Clinical Research Ethics Committee due to the retrospective design. The study results are reported following the STROBE recommendations [28] (Supplementary Material).

2.3. Participants

All adult (≥18 years) onco-hematological neutropenic patients, including hematopoietic stem cell transplant (HSCT) recipients, were eligible for the study if they were diagnosed with at least one episode of PA BSI during the study period. Subsequent episodes caused by PA occurring in the same patient were included in the study if they occurred at intervals of >1 month. Only monomicrobial PA BSI episodes were selected for this study. The exclusion criteria were unavailability of key data (related to death) and polymicrobial BSI. The follow-up period was 30 days from BSI onset.

2.4. Variables

Data regarding baseline characteristics, clinical and microbiological features and endpoints were collected. Empirical antibiotic therapy was considered when the antibiotic was administered before reception of definitive susceptibility results. Appropriate empirical antibiotic therapy was defined when patients received at least one in vitro active antibiotic against the PA strain. Empirical combination therapy was considered appropriate when both antibiotics that were empirically administered were active against the PA strain. If a patient received two empirical antibiotics but only one was active, this was considered appropriate monotherapy. Inappropriate empirical antibiotic treatment (IEAT) was considered when the patient did not receive any empirical antibiotic with in vitro activity or an empirical antibiotic therapy was lacking. In addition, in the cohort of patients with PA pneumonia, empirical monotherapy with an aminoglycoside was considered inappropriate. Thus, three treatment categories were observed: appropriate empirical combination therapy, appropriate empirical monotherapy and IEAT. The antipseudomonal β-lactams
were uniformly administered at the current standard doses for the treatment of febrile neutropenia [26,29]. In case of renal impairment, the dosing was adjusted accordingly.

2.5. Outcomes

The 30-day case-fatality rate of patients with bacteremic PA pneumonia was compared with those with BSI from other sources. The rate of persistent BSI, need for intensive care unit (ICU) admission and mechanical ventilation were also analyzed. Risk factors for overall 30-day case-fatality and the effect of the use of appropriate combination antibiotic empirical therapy, monotherapy or IEAT on mortality were analyzed only in patients with PA pneumonia.

2.6. Microbiological Studies

Clinical samples were processed at the microbiology laboratories of each participating center in accordance with standard operating procedures. PA was identified using standard microbiological techniques at each center. In vitro susceptibility was determined according to the EUCAST recommendations [30], except at the Lebanese center and at one center from Argentina where the CLSI breakpoints were used, and in the center in the UK where the BSAC recommendations were used before 2016 [31]. PA isolate phenotypes were stratified in accordance with recent standard definitions [32].

2.7. Definitions

Neutropenia and severe neutropenia were defined as an absolute neutrophil count below $0.5 \times 10^9$ cells/mm$^3$ and $0.1 \times 10^9$ cells/mm$^3$, respectively. Previous corticosteroid treatment was defined as the administration of $\geq 20$ mg of prednisone, or equivalent dosing, for at least four weeks within 30 days of BSI onset. Patients with refractory/relapsed disease and those receiving palliative chemotherapy were classified as having refractory disease.

Bacteremic PA pneumonia was defined as the presence of an acute respiratory illness and a new pulmonary infiltrate on a chest radiograph and/or CT in association with concurrent PA BSI. Other BSI sources were established using standard US Centers for Disease Control and Prevention criteria for secondary BSI [33]. In addition, the source of BSI was defined as unknown or endogenous in patients in whom no other sources were identified. Septic shock was defined as a systolic blood pressure $< 90$ mmHg that was unresponsive to fluid treatment or required vasoactive drug therapy [34]. Mucositis was considered in patients with ulcerative lesions involving only the oral cavity. Comorbidities were defined as the presence of one or more of the following diseases: chronic obstructive pulmonary disease, heart disease, hepatic disease, diabetes mellitus, renal failure and cerebrovascular disease. Persistent BSI was considered if blood cultures were positive after 48 h of adequate antibiotic therapy. The 30-day case-fatality rate was defined as death from any cause within 30 days of BSI onset.

2.8. Statistical Analysis

To define cohort characteristics, categorical variables were presented as the number of cases and percentages, while continuous variables were presented as the mean and standard deviation (SD) or median and interquartile range (IQR). Continuous variables were compared using the Student’s $t$-test or the Mann–Whitney U test where appropriate. Fisher’s exact test or Pearson’s $\chi^2$ test were applied to assess the relationship between categorical variables.
Time until death, or last follow-up, was assessed using the Kaplan–Meier estimator. The log-rank test was used to compare the survival curves between treatment strategies. The Cox proportional hazards model was used to perform an adjusted analysis of the treatment strategies with age, sex, septic shock and the presence of multidrug resistance as clinically relevant factors. The proportionality of risks in the Cox model was checked using the Schoenfeld residuals. The presence of septic shock at admission violated the proportional hazard assumption of the Cox model. To address this problem, we performed a time-dependent covariates analysis on septic shock. Data were split into three groups (from day 0 to day 2, from day 2 to day 10, and from day 10 to day 30), defined after the exploration of the Schoenfeld residuals plot, to estimate different coefficients over different time intervals [35]. The effects of the treatment strategies were reported with hazard ratio (HR) and 95% confidence interval adjusted for age, sex, and multi-drug resistant pneumonia. Statistical analyses were performed with R software 4.1.0.

3. Results
3.1. Clinical Characteristics

Among the 1217 eligible PA BSI episodes, pneumonia was the second most frequent source, with 311 episodes (25.5%), after an endogenous source (37.4%). Two hundred episodes met at least one of the exclusion criteria and were excluded from the analysis, leaving 1017 included episodes, in which pneumonia was the source of BSI in 294 (28.9%). Baseline characteristics of patients included in the study are detailed in the supplementary material (Table S1). Patients with bacteremic PA pneumonia had more comorbidities and presented more frequently with septic shock than those with PA BSI from other sources. In total, 17.7% (52/294) of PA pneumonia episodes were caused by multidrug-resistant (MDR) strains, and 30.6% (90/294) were due to carbapenem-resistant isolates, without significant differences between groups.

3.2. Treatment Characteristics

Table 1 shows the different treatment regimens administered in patients with PA pneumonia. Overall, an antipseudomonal $\beta$-lactam in monotherapy was the most frequent empirical antibiotic used (173/294, 58.9%). When a combination empirical therapy was preferred, a combination of a $\beta$-lactam plus an aminoglycoside was predominant (87/118, 73.7%). Of note, 68 episodes (23.1%) received IEAT, particularly when the PA BSI was caused by an MDR strain [38/52 (73.1%) vs. 30/242 (12.4%); $p < 0.001$]. Almost 49% of these 68 episodes were initially treated with an antipseudomonal $\beta$-lactam in monotherapy with no in vitro activity against the PA isolate (mainly carbapenems or piperacillin/tazobactam). Compared with PA BSI from other sources, no differences were found between the rate of inappropriate empirical antibiotic treatment [68/294 (23.1%) vs. 142/723 (19.6%); $p = 0.29$]. Among those episodes caused by a MDR PA strain, only 14 received an appropriate empirical antibiotic treatment that was mainly based on a monotherapy (10 of 14 cases).
Table 1. Treatment characteristics of the 294 patients with _Pseudomonas aeruginosa_ bacteremic pneumonia.

| Treatment Characteristics | No Antibiotic Treatment (Death < 48 h) | Initial empirical monotherapy | Initial empirical combination therapy | Appropriate empirical treatment | Inappropriate empirical treatment |
|---------------------------|---------------------------------------|--------------------------------|-------------------------------------|---------------------------------|----------------------------------|
|                           | 3/294 (1)                             | 173/294 (58.9)               | 118/294 (40.1)                      | 226/294 (76.9)                  | 68/294 (23.1)                   |
| No Antibiotic Treatment   |                                       |                                |                                     |                                 |                                  |
| Initial empirical         | 3/294 (1)                             | 173/294 (58.9)               | 118/294 (40.1)                      | 226/294 (76.9)                  | 68/294 (23.1)                   |
| monotherapy               | 84 (48.6)                             | 54 (31.2)                     | 2 (1.1)                             | 1 (0.6)                         | 1 (0.6)                         |
| Piperacillin/tazobactam   |                                       |                                |                                     |                                 |                                  |
| Antipseudomonal           | 84 (48.6)                             | 54 (31.2)                     | 2 (1.1)                             | 1 (0.6)                         | 1 (0.6)                         |
| carbapenems (imipenem,    |                                       |                                |                                     |                                 |                                  |
| meropenem)                |                                       |                                |                                     |                                 |                                  |
| Antipseudomonal           | 84 (48.6)                             | 54 (31.2)                     | 2 (1.1)                             | 1 (0.6)                         | 1 (0.6)                         |
| cephalosporins            |                                       |                                |                                     |                                 |                                  |
| Polymyxins (Colistin/     |                                       |                                |                                     |                                 |                                  |
| Polymyxin B)              |                                       |                                |                                     |                                 |                                  |
| Polymyxins (Colistin,     |                                       |                                |                                     |                                 |                                  |
| Polymyxin B)              |                                       |                                |                                     |                                 |                                  |
| Fluoroquinolones          |                                       |                                |                                     |                                 |                                  |
| Aminoglycoside            |                                       |                                |                                     |                                 |                                  |
| Others a                   |                                       |                                |                                     |                                 |                                  |
| Initial empirical         | 118/294 (40.1)                        | 173/294 (58.9)               | 118/294 (40.1)                      | 226/294 (76.9)                  | 68/294 (23.1)                   |
| combination therapy       | 7 (4)                                 | 84 (48.6)                     | 87 (73.7)                           | 87 (73.7)                       | 87 (73.7)                       |
| β-lactam + AG             |                                       |                                |                                     |                                 |                                  |
| β-lactam + non-AG         | 87 (73.7)                             | 84 (48.6)                     | 27 (22.9)                           | 27 (22.9)                       | 27 (22.9)                       |
| Non-β-lactam combination  | 2 (1.4)                               | 1 (0.6)                       | 2 (1.7)                             | 2 (1.7)                         | 2 (1.7)                         |
| Appropriate empirical      | 226/294 (76.9)                        | 173/294 (58.9)               | 118/294 (40.1)                      | 226/294 (76.9)                  | 68/294 (23.1)                   |
| treatment b               | 147/226 (65)                          | 84 (48.6)                     | 87 (73.7)                           | 87 (73.7)                       | 87 (73.7)                       |
| Monotherapy               |                                       |                                |                                     |                                 |                                  |
| Piperacillin/tazobactam   | 73 (49.7)                             | 54 (31.2)                     | 2 (1.1)                             | 1 (0.6)                         | 1 (0.6)                         |
| Anti-pseudomonal carbapenems (imipenem, meropenem) | 37 (25.2) | 54 (31.2) | 2 (1.1) | 1 (0.6) | 1 (0.6) |
| Anti-pseudomonal          | 59 (47.7)                             | 37 (25.2)                     | 27 (22.9)                           | 27 (22.9)                       | 27 (22.9)                       |
| cephalosporins            |                                       |                                |                                     |                                 |                                  |
| Polymyxins (Colistin,     | 12 (8.2)                              | 12 (8.2)                      | 12 (8.2)                            | 12 (8.2)                        | 12 (8.2)                        |
| Polymyxin B)              |                                       |                                |                                     |                                 |                                  |
| Fluoroquinolone           |                                       |                                |                                     |                                 |                                  |
| levofloxacin/ciprofloxacin|                                       |                                |                                     |                                 |                                  |
| Combined therapy          | 79/226 (35)                           | 84 (48.6)                     | 87 (73.7)                           | 87 (73.7)                       | 87 (73.7)                       |
| β-lactam + AG             | 59 (74.7)                             | 54 (31.2)                     | 59 (74.7)                           | 59 (74.7)                       | 59 (74.7)                       |
| β-lactam + non-AG         | 20 (25.3)                             | 27 (22.9)                     | 20 (25.3)                           | 20 (25.3)                       | 20 (25.3)                       |
| Inappropriate empirical    | 68/294 (23.1)                         | 173/294 (58.9)               | 118/294 (40.1)                      | 226/294 (76.9)                  | 68/294 (23.1)                   |
| treatment b               | 3/68 (4.4)                            | 84 (48.6)                     | 87 (73.7)                           | 87 (73.7)                       | 87 (73.7)                       |
| Monotherapy               | 41/68 (60.3)                          | 84 (48.6)                     | 87 (73.7)                           | 87 (73.7)                       | 87 (73.7)                       |
| No antibiotic treatment   | 16 (39)                               | 16 (39)                       | 16 (39)                             | 16 (39)                         | 16 (39)                         |
| (Death < 48 h)            |                                       |                                |                                     |                                 |                                  |
| Piperacillin/tazobactam   | 15 (36.6)                             | 15 (36.6)                     | 15 (36.6)                           | 15 (36.6)                       | 15 (36.6)                       |
| Anti-pseudomonal          | 2 (4.9)                               | 2 (4.9)                       | 2 (4.9)                             | 2 (4.9)                         | 2 (4.9)                         |
| cephalosporins            |                                       |                                |                                     |                                 |                                  |
| Aminoglycosides           | 1 (2.4)                               | 1 (2.4)                       | 1 (2.4)                             | 1 (2.4)                         | 1 (2.4)                         |
| Others c                  | 7 (17)                                | 7 (17)                        | 7 (17)                              | 7 (17)                          | 7 (17)                          |
| Combination therapy       | 24/68 (35.3)                          | 173/294 (58.9)               | 118/294 (40.1)                      | 226/294 (76.9)                  | 68/294 (23.1)                   |
| β-lactam + AG             | 21 (87.5)                             | 84 (48.6)                     | 87 (73.7)                           | 87 (73.7)                       | 87 (73.7)                       |
| β-lactam + non-AG         | 1 (4.2)                               | 54 (31.2)                     | 27 (22.9)                           | 27 (22.9)                       | 27 (22.9)                       |
| Non-β-lactam combination  | 2 (8.3)                               | 2 (8.3)                       | 2 (8.3)                             | 2 (8.3)                         | 2 (8.3)                         |

Qualitative data are expressed as numbers (%), unless otherwise indicated. Abbreviations: AG: Aminoglycoside. 

a Clindamycin (n = 1), Azithromycin (n = 1), Ceftriaxone (n = 2), Amoxicillin/clavulanate (n = 2), Metronidazole (n = 1). 

b 12 patients received an initial empirical combination treatment but were classified as receiving an appropriate empirical monotherapy because only one of the antibiotics showed in vitro activity against the PA strain: Colistin (n = 9), fluoroquinolone (n = 1), antipseudomonal cephalosporin (n = 1), piperacillin/tazobactam (n = 1). 

c Amoxicillin/clavulanate (n = 2), Ceftriaxone (n = 2), Metronidazole (n = 1), Clindamycin (n = 1), Azithromycin (n = 1). 

d 19 episodes received inappropriate empirical combination antibiotic treatment where only the aminoglycoside showed in vitro activity against the PA isolate.

3.3. Outcomes

The 30-day case-fatality rate was significantly higher in patients with PA bacteremic pneumonia than in those with PA BSI from other sources (Table 2). Moreover, the rates of persistent BSI and the need for ICU admission and mechanical ventilation were also higher in patients with pneumonia.
### 3.4. Risk Factors for Mortality in Patients with Bacteremic PA Pneumonia

In the univariate Cox analysis, septic shock at presentation (HR 3.56 [95%CI 2.56–4.94]; \(p < 0.001\)), infection due to a MDR strain (HR 2.05 [95%CI 1.43–2.93]; \(p < 0.001\)) and IEAT (HR 1.57 [95%CI 1.21–2.21]; \(p = 0.009\)) were associated with higher 30-day case-fatality rate, whereas the use of an appropriate empirical combination treatment was associated with improved survival (HR 0.46 [95%CI 0.29–0.72]; \(p = 0.001\)). In the multivariate Cox analysis, receiving IEAT was an independent risk factor for increased 30-day case-fatality (aHR 1.44 [95%CI 1.01–2.03]; \(p = 0.042\)).

In addition, when focusing on the impact of the three treatment strategies, we observed that the benefit on survival of the administration of an appropriate empirical combination treatment was maintained after adjusting for potential confounders (aHR 0.46 [95%CI 0.27–0.78]; \(p = 0.004\)). The univariate and multivariate Cox models are detailed in Tables 3 and 4. Figures 1 and 2 show the Kaplan–Meier curves stratified by the appropriateness of empirical treatment.

### Table 2. Outcomes.

| Outcome                       | PA Pneumonia \(n = 294\) (%) | PA BSI \(n = 723\) (%) | \(p\)-Value |
|-------------------------------|-------------------------------|-------------------------|-------------|
| 30-day case-fatality rate     | 162 (55.1)                   | 227 (31.4)              | <0.001      |
| Persistent BSI (48h from BSI onset) | 41 (14.5)                  | 71 (9.9)                | 0.048       |
| ICU admission                 | 126 (42.9)                   | 186 (25.7)              | <0.001      |
| Need for mechanical ventilation | 83 (28.2)                    | 115 (15.9)              | <0.001      |

Abbreviations: PA: Pseudomonas aeruginosa, BSI: Bloodstream infection, ICU: Intensive care unit.

### Table 3. Univariate Cox model for the 30-day case-fatality rate in patients with PA bacteremic pneumonia.

| Variables                                | Alive \(n = 132\) | Dead \(n = 162\) | HR   | CI 95% | \(p\)-Value |
|------------------------------------------|-------------------|------------------|------|--------|-------------|
| Age (y), mean (SD)                       | 61.6 (14.8)       | 61.1 (13.6)      | 1.00 | 0.99–1.01 | 0.781       |
| Gender (female)                          | 41 (31.1)         | 51 (31.5)        | 1.13 | 0.81–1.58 | 0.534       |
| Acute leukemia                           | 39 (29.5)         | 56 (34.6)        | 1.12 | 0.81–1.55 | 0.448       |
| Refractory disease                       | 48 (36.4)         | 71 (43.8)        | 1.29 | 0.95–1.76 | 0.122       |
| HSCT                                     | 20 (15.2)         | 35 (21.6)        | 1.17 | 0.81–1.71 | 0.344       |
| GVHD                                     | 7 (43.8)          | 14 (48.3)        | 1.09 | 0.53–2.27 | 0.806       |
| Comorbidities \(a\)                     | 77 (62.1)         | 95 (60.1)        | 0.97 | 0.71–1.34 | 0.810       |
| BSI acquisition (hospital-acquired)      | 58 (43.9)         | 88 (54.3)        | 1.18 | 0.87–1.61 | 0.223       |
| Prior corticosteroid treatment (1 month) | 71 (53.8)         | 94 (58.8)        | 1.13 | 0.83–1.55 | 0.417       |
| Severe neutropenia                       | 68 (54)           | 96 (59.6)        | 1.26 | 0.92–1.73 | 0.165       |
| Septic shock                             | 34 (26)           | 107 (66)         | 3.56 | 2.56–4.94 | <0.001      |
| Multidrug-resistant strain               | 11 (8.3)          | 41 (25.3)        | 2.05 | 1.43–2.93 | <0.001      |
| Inappropriate empirical antibiotic treatment | 21 (15.9)       | 47 (29.0)        | 1.57 | 1.21–2.21 | 0.009       |

Abbreviations: PA: Pseudomonas aeruginosa; BSI: bloodstream infection; HSCT: Hematopoietic stem cell transplant; GVHD: Graft versus host disease; HR: Hazard Ratio; CI: Confidence Interval. \(a\) Comorbidities are defined as the presence of one or more of the following diseases: COPD, heart or hepatic disease, diabetes mellitus, renal failure, and cerebrovascular disease.
Table 4. Multivariate Cox model for the 30-day case-fatality rate in patients with PA bacteremic pneumonia.

| Predictors                                      | aHR     | Std. Error | CI 95%    | p-Value |
|------------------------------------------------|---------|------------|-----------|---------|
| Age                                            | 1.00    | 0.01       | 0.99–1.01 | 0.616   |
| Gender                                         | 1.17    | 0.20       | 0.83–1.64 | 0.376   |
| Inappropriate empirical antibiotic treatment    | 1.44    | 0.26       | 1.01–2.03 | 0.042   |
| **Septic shock**                                |         |            |           |         |
| Group 1 (0–48 h from BSI onset)                 | 6.53    | 1.87       | 3.73–11.43| <0.001  |
| Group 2 (48 h–10 days from BSI onset)           | 2.89    | 0.22       | 1.66–5.05 | <0.001  |
| Group 3 (10 days–30 days from BSI onset)        | 1.41    | 0.58       | 0.63–3.14 | 0.400   |

Abbreviations: PA: Pseudomonas aeruginosa; BSI: bloodstream infection; aHR: adjusted Hazard Ratio, CI: Confidence Interval.

Figure 1. Kaplan–Meier survival analysis of patients with *Pseudomonas aeruginosa* bacteremic pneumonia, stratified by the appropriateness of empirical treatment.
Figure 2. Kaplan–Meier survival analysis of patients with *Pseudomonas aeruginosa* bacteremic pneumonia, stratified by treatment group.

4. Discussion

In this large multicenter, international cohort study of high-risk neutropenic cancer patients, we found that pneumonia was a frequent cause of PA BSI and was associated with a strikingly high 30-day case-fatality rate. Among patients with bacteremic PA pneumonia, the presence of septic shock and the use of an IEAT had a negative impact on overall survival. Conversely, the administration of appropriate initial combined empirical antibiotic treatment, mainly based on an active antipseudomonal β-lactam and an aminoglycoside, was independently associated with improved outcomes.

We found that 23% of patients with bacteremic PA pneumonia received IEAT, a percentage that rose significantly in the case of MDR strains. IEAT was also found to be an independent risk factor for mortality; indeed, it has previously been shown to have a detrimental effect on mortality in neutropenic cancer patients with PA BSI [3,4,6,36] and bacteremic PA pneumonia [7,14]. However, the presence of multidrug resistance was not independently associated with a poor prognosis in our study. In this regard, even though the association between IEAT and multidrug resistance has been previously reported [3,37], its real impact on mortality is still controversial [6,7,12,13,38].

In the current era of emerging antibiotic resistance, it seems reasonable to opt for initial empirical combination treatment in order to increase the probability of adequateness and also to take advantage of the potential antibiotics’ synergism [39]. Nevertheless, the benefit for survival of using a combined empirical antibiotic therapy rather than monotherapy to treat PA severe infections in the general population remains a long-standing controversy [8,37,40]. Specifically, when focusing on PA bacteremic pneumonia, Park et al.
found that the use of adequate combined empirical antibiotic treatment was associated with improved 28-day survival and higher 2 and 4-week bacterial eradication rates [7]. Conversely, Recio et al. did not confirm this beneficial effect on mortality [5]; however, these authors found neutropenia to be a risk factor for early 5-day mortality.

Importantly, this knowledge gap is even greater in the setting of febrile neutropenia [41]. Indeed, a meta-analysis by Paul et al. focusing on neutropenic cancer patients found no benefit of combination therapy, although the rate of PA infections was only 1.7% and the number of pneumonia episodes was not specified [11].

Of note, we found that the use of a combined empirical antibiotic treatment for PA bacteremic pneumonia in neutropenic patients, mainly based on a $\beta$-lactam and an aminoglycoside, was associated with improved 30-day mortality. Our results may be explained by the synergistic effect of combining an adequate $\beta$-lactam antibiotic and aminoglycoside, as suggested by early studies [42]. In this line, in a previous study, we observed an improved early (7-day) mortality rate in those neutropenic cancer patients with GNB BSI who received initial appropriate combination therapy [39]. In addition, the beneficial effect of adding an aminoglycoside to an active $\beta$-lactam has recently been shown to be particularly relevant in febrile neutropenic patients presenting with septic shock [43]. Similarly, in our study, the beneficial effect of a combined therapy over monotherapy was mainly observed within the first 7 days of BSI onset, probably when the empirical use of an aminoglycoside is more important to increase the rate of bacterial clearance and consequently improve outcomes.

In this regard, choosing the optimal empirical $\beta$-lactam for the treatment of PA pneumonia according to the individual risk of resistance is crucial. Here, the newly available $\beta$-lactam + $\beta$-lactamase inhibitors may play a very important role [44,45]. The use of colistin instead of an aminoglycoside is an appealing proposal, but no firm conclusions regarding its appropriateness can be drawn from the present study; however, it is an empirical treatment strategy that urgently deserves further investigation.

The main strength of this study is that it is based on one of the largest cohorts of neutropenic cancer patients with PA pneumonia, with a multicenter international design, that allows the generalization of the results. To account for a possible bias, multivariate Cox analyses were performed with septic shock as a time-dependent variable. Nevertheless, this study also has some limitations that should be acknowledged. First, this was not a randomized clinical trial (RCT); thus, the choice of therapy may have been influenced by patient-related variables and by the clinical presentation. Second, we included various empirical combination antibiotic regimens, which may have had different effects on mortality. Finally, some information may have been lost due to the retrospective design, and we may not have adequately controlled for certain confounders.

5. Conclusions

In conclusion, we found that appropriate initial combination antibiotic empirical treatment improved 30-day mortality compared with monotherapy in neutropenic patients with PA bacteremic pneumonia. Therefore, combination empirical therapy should be promptly administered in febrile neutropenic patients with suspected pneumonia as the source of infection. However, further RCTs are warranted to confirm our results.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms10040733/s1, detailed list of the number of participating centers in each country and Table S1. Clinical and microbiological characteristics of patients with Pseudomonas aeruginosa bacteremic pneumonia.
Author Contributions: Conceptualization, A.A.-P., C.G. and J.C.; methodology, A.A.-P., A.B., C.G. and J.C.; validation, A.A.-P., C.G. and J.C.; formal analysis, N.P.; investigation, A.A.-P., A.B., C.G. and J.C.; resources, C.G. and J.C.; data curation, A.A.-P., X.D.-M., J.L.-A., A.M. (Alberto Mussetti), I.R.-C., P.P.-A., E.A., C.O., M.A., J.M.M., M.M. (Malgorzata Mikulski), P.M.-D., F.H., O.G., L.D., H.M.P.M., A.-S.B., E.G., B.I., W.V.K., P.R.-G., J.M.A., M.M. (Milagros Montero), S.S.K., O.R.S., S.C., I.M.-G., J.I.M., M.Z.R.G., P.H., R.A., M.P., J.L.d.P., L.Y., R.T., A.M. (Adriana Manzur), A.N., A.B., C.G. and J.C.; writing—original draft preparation, A.A.-P., C.G. and J.C.; writing—review and editing, A.A.-P., C.G. and J.C.; funding acquisition, A.A.-P., C.G. and J.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) [CB21/13/0009, CB21/13/00079, CB21/13/00054, CB21/13/00086, CB21/13/00012], Madrid, Spain.

Institutional Review Board Statement: The study was approved by the Institutional Review Board at Bellvitge University Hospital (local reference number PR408/17) and by the local Research Ethics Committees at the participating centers. It was conducted in accordance with the Declaration of Helsinki guidelines.

Informed Consent Statement: The need for informed consent was waived by the Clinical Research Ethics Committee due to the retrospective design. The study results are reported following the STROBE recommendations [28] (Supplementary Material).

Data Availability Statement: Not applicable.

Acknowledgments: We thank the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES) and the ESCMID Study Group for Immunocompromised Hosts (ESGICH) for supporting the study. We thank Centres de Recerca de Catalunya (CERCA) Program and Generalitat de Catalunya for institutional support. We thank the Spanish Network for Research in Infectious Diseases and the Rio Hortega program of the Instituto de Salud Carlos III for the financial support of pre-doctoral students X. Durá, J. Laporte-Amargós and A. Albasa-Puig.

Conflicts of Interest: F.H. received speaker’s fees from MSD and Pfizer and Research and Educational grants from Pfizer. P.R.-G. received speaker’s fees from MSD, Menarini and Shionogi.

References

1. Cattaneo, C.; Antoniazzi, F.; Casari, S.; Ravizzola, G.; Gelmi, M.; Pagani, C.; D’Adda, M.; Morello, E.; Re, A.; Borlenghi, E.; et al. P. aeruginosa bloodstream infections among hematological patients: An old or new question? Ann. Hematol. 2012, 91, 1299–1304. [CrossRef] [PubMed]

2. Tofas, P.; Samarkos, M.; Piperaki, E.T.; Kosmidis, C.; Triantafyllopoulos, I.D.; Kotsopoulos, M.; Pantazatou, A.; Perlorentzou, S.; Poulli, A.; Avgia, M.; et al. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: Risk factors, treatment and outcome. Diagn. Microbiol. Infect. Dis. 2017, 88, 335–341. [CrossRef] [PubMed]

3. Martinez-Nadal, G.; Puerta-Alcalde, P.; Gudiol, C.; Cardozo, C.; Albasanz-Puig, A.; Marco, F.; Laporte-Amargós, J.; Moreno-García, E.; Domingo-Domenech, M.; Chumbita, M.; et al. Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients with Bacteremia in the Era of Multidrug Resistance. Clin. Infect. Dis. 2020, 70, 1068–1074. [CrossRef] [PubMed]

4. Kim, Y.J.; Jun, Y.H.; Kim, Y.R.; Park, K.G.; Park, Y.J.; Kang, J.Y.; Kim, S.I. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: retrospective study of impact of combination antimicrobial therapy. BMC Infect. Dis. 2014, 14, 1–7. [CrossRef]

5. Recio, R.; Viedma, E.; González-Bodí, S.; Villa, J.; Orellana, M.A.; Manchego-Losa, M.; Lora-Tamayo, J.; Chaves, F. Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia. Int. J. Antimicrob. Agents 2021, 58, 106450. [CrossRef]

6. Trecarichi, E.M.; Tumbarello, M.; Caira, M.; Candoni, A.; Cattaneo, C.; Pastore, D.; Fanci, R.; Nosari, A.; Vianelli, N.; Busca, A.; et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011, 96, 32–34. [CrossRef]

7. Park, S.Y.; Park, H.J.; Moon, S.M.; Park, K.H.; Chong, Y.P.; Kim, M.N.; Kim, S.H.; Lee, S.O.; Kim, Y.S.; Woo, J.H.; et al. Impact of adequate empirical combination therapy on mortality from bacteraemic Pseudomonas aeruginosa pneumonia. BMC Infect. Dis. 2012, 12, 1. [CrossRef]

8. Peña, C.; Suarez, C.; Ocampo-Sosa, A.; Murillas, J.; Almirante, B.; Pomar, V.; Aguilar, M.; Granados, A.; Calbo, E.; Rodriguez-Baño, J.; et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in pseudomonas aeruginosa bloodstream infections: A post hoc analysis of a prospective cohort. Clin. Infect. Dis. 2013, 57, 208–216. [CrossRef]
9. Bowers, D.R.; Liew, Y.X.; Lye, D.C.; Kwa, A.L.; Hsu, L.Y.; Tam, V.H. Outcomes of appropriate empiric combination versus monotherapy for pseudomonas aeruginosa bacteremia. *Antimicrob. Agents Chemother.* 2013, 57, 1270–1274. [CrossRef]

10. Paul, M.; Leibovici, L. Combination therapy for pseudomonas aeruginosa bacteremia: Where do we stand? *Clin. Infect. Dis.* 2013, 57, 217–220. [CrossRef]

11. Paul, M.; Dickstein, Y.; Schlesinger, A.; Grozinsky-Glasberg, S.; Soares-Weiser, K.; Leibovici, L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. *Cochrane Database Syst. Rev.* 2013, 2013, CD003038. [CrossRef]

12. Babich, T.; Naucler, P.; Valik, J.K.; Giske, C.G.; Benito, N.; Cardona, R.; Rivera, A.; Pulcini, C.; Fattah, M.A.; Haquin, J.; et al. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteremia: A retrospective multicentre study. *Int. J. Antimicrob. Agents* 2020, 55, 105847. [CrossRef]

13. Recio, R.; Mancheño, M.; Viedma, E.; Villa, J.; Orellana, M.A.; Lora-Tamayo, J.; Chaves, F. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence. *Antimicrob. Agents Chemother.* 2020, 64, 1–13. [CrossRef]

14. Joo, E.J.; Kang, C.I.; Ha, Y.E.; Park, S.Y.; Kang, S.J.; Wi, Y.M.; Lee, N.Y.; Chung, D.R.; Peck, K.R.; Song, J.H. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteremia: A stratified analysis according to sites of infection. *Infection* 2011, 39, 309–318. [CrossRef]

15. Lanoix, J.P.; Schmit, J.L.; Douadi, Y. Bacterial lung sepsis in patients with febrile neutropenia. *Curr. Opin. Palmed. Med.* 2012, 18, 175–180. [CrossRef]

16. Specchia, G.; Pastore, D.; Carluccio, P.; Mele, G.; Montagna, M.T.; Liso, A.; Rizzi, R.; Stabile Ianora, A.; Liso, V. Pneumonia in acute leukemia patients during induction therapy: Experience in a single institution. *Leuk. Lymphoma* 2003, 44, 97–101. [CrossRef]

17. Aguilar-Guisado, M.; Jiménez-Jambrina, M.; Espigado, I.; Rovira, M.; Martino, R.; Oriol, A.; Borrell, N.; Ruiz, I.; Martín-Dávila, P.; de la Cámara, R.; et al. Pneumonia in allogeneic stem cell transplantation recipients: A multicenter prospective study. *Clin. Transplant.* 2011, 25, 629–638. [CrossRef]

18. Hakki, M.; Limaye, A.P.; Kim, H.W.; Kirby, K.A.; Corey, L.; Boeckh, M. Invasive Pseudomonas aeruginosa infections: High rate of recurrence and mortality after hematopoietic cell transplantation. *Bone Marrow Transplant.* 2007, 39, 687–693. [CrossRef]

19. Rabello, L.S.C.F.; Silva, J.R.L.; Azevedo, L.C.F.; Souza, I.; Torres, V.M.; Rosolem, M.M.; Lisboa, T.; Soares, M.; Salluh, J.I.F. Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: A prospective cohort study. *PloS ONE* 2015, 10, e0120544. [CrossRef]

20. Guarana, M.; Nucci, M.; Noeur, S.A. Shock and early death in hematologic patients with febrile neutropenia. *Antimicrob. Agents Chemother.* 2019, 63, 1–25. [CrossRef]

21. Gudiol, C.; Royo-Cebrecos, C.; Laporte, J.; Ardanuy, C.; Garcia-Vidal, C.; Antonio, M.; Arnau, M.; Carratalá, J. Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. *Respirology* 2016, 21, 1411–1418. [CrossRef]

22. Carratalá, J.; Rosón, B.; Fernández-Sevilla, A.; Alcaide, F.; Gudiol, F. Bacteremic Pneumonia in Neutropenic Patients with Cancer. *Arch. Intern. Med.* 1998, 158, 868. [CrossRef]

23. Gruson, D.; Vargas, E.; Hilbert, G.; Bui, N.; Maillot, T.; Mayet, T.; Pillot, O.; Chene, G.; Gbikpi-Benissan, G. Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia. *Intensive Care Med.* 2004, 30, 965–971. [CrossRef]

24. Vuotto, F.; Berthon, C.; Lemaître, N.; Duhamel, A.; Balkaran, S.; Le Ray, E.; Micol, J.B.; Faure, K.; Alfandari, S. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: A case-control study. *Am. J. Infect. Control* 2013, 41, 527–533. [CrossRef]

25. Kalil, A.C.; Mettersky, M.L.; Klompas, M.; Muscedere, J.; Sweeney, D.A.; Palmer, L.B.; Napolitano, L.M.; O’Grady, N.P.; Bartlett, J.G.; Carratalá, J.; et al. Executive Summary: Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin. Infect. Dis.* 2016, 63, 575–582. [CrossRef]

26. Averbuch, D.; Orasch, C.; Cordonnier, C.; Livermore, D.M.; Viscoli, C.; Gyssens, I.C.; Kern, W.V.; Klyasova, G.; Marchetti, O.; Engelhard, D. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance. *Haematologica* 2013, 98, 1826. [CrossRef]

27. Gudiol, C.; Albansanz-Puig, A.; Laporte-Amargós, J.; Pallarès, N.; Mussetti, A.; Ruiz-Camps, I.; Puerta-Alcalde, P.; Abdala, E.; Oltolini, C.; Akova, M.; et al. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa. *Antimicrob. Agents Chemother.* 2020, 64, 1–12. [CrossRef]

28. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gotzsche, P.C.; Vandenbroucke, J.P. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. *BMJ* 2007, 335, 806–808. [CrossRef]

29. Freifeld, A.G.; Bov, E.J.; Sepkowitz, K.A.; Boeckh, M.J.; Ito, J.I.; Mullen, C.A.; Raad, I.I.; Rolston, K.V.; Young, J.A.H.; Wingard, J.R. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* 2011, 52, e56–e93. [CrossRef]

30. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for Interpretation of MICs and Zone Diameters. Version 12.0. 2022. Available online: http://www.eucast.org (accessed on 23 February 2022).

31. Wootton, M. Laboratory Methods for Antimicrobial Susceptibility Testing. In *Antimicrobial/Anti-Infective Materials*; CRC Press: Boca Raton, FL, USA, 1999; Volume 44, pp. 308–332.
32. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 2012, 18, 268–281. [CrossRef]

33. Garner, J.S.; Jarvis, W.R.; Emori, T.G.; Horan, T.C.; Hughes, J.M. CDC definitions for nosocomial infections, 1988. *Am. J. Infect. Control* 1988, 16, 128–140. [CrossRef]

34. Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.M.; French, C.; Machado, F.R.; McIntyre, L.; Ostermann, M.; Prescott, H.C.; et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. *Intensive Care Med.* 2021, 47, 1181–1247. [CrossRef] [PubMed]

35. Therneau, T.M.; Grambsch, P.M. *Modeling Survival Data: Extending the Cox Model*, Statistics for Biology and Health, 1st ed.; Springer: New York, NY, USA, 2000; ISBN 978-1-4419-3161-0.

36. Righi, E.; Peri, A.M.; Harris, P.N.A.; Wailan, A.M.; Liborio, M.; Lane, S.W.; Paterson, D.L. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: Systematic review and meta-analysis. *J. Antimicrob. Chemother.* 2017, 72, 668–677. [CrossRef] [PubMed]

37. Deconinck, L.; Meybeck, A.; Patoz, P.; Van Grunderbeeck, N.; Boussekey, N.; Chiche, A.; Delannoy, P.Y.; Georges, H.; Leroy, O. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. *Infect. Dis.* 2017, 49, 396–404. [CrossRef] [PubMed]

38. Suárez, C.; Peña, C.; Gavaldà, L.; Tubau, F.; Manzur, A.; Domínguez, M.A.; Pujol, M.; Gudiol, F.; Ariza, J. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. *Int. J. Infect. Dis.* 2010, 14 (Suppl. 3), e73–e78. [CrossRef]

39. Albasanz-Puig, A.; Gudiol, C.; Puerta-Alcalde, P.; Ayaz, C.M.; Machado, M.; Herrera, F.; Martín-Dávila, P.; Laporte-Amargós, J.; Cardozo, C.; Akova, M.; et al. Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: A Propensity-Matched Cohort Study (AMINOLACTAM Study). *Antimicrob. Agents Chemother.* 2021, 65, e00045-21. [CrossRef]

40. Vardakas, K.Z.; Tansarli, G.S.; Bliziotis, I.A.; Falagas, M.E. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis. *Int. J. Antimicrob. Agents* 2013, 41, 301–310. [CrossRef]

41. McCarthy, K.L.; Cherian, J.D.; Avent, M.L.; Paterson, D.L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteremia in febrile neutropenic patients? The question still remains. *Infect. Dis.* 2018, 50, 403–406. [CrossRef]

42. Giamarellou, H. Aminoglycosides plus β-lactams against gram-negative organisms: Evaluation of in vitro synergy and chemical interactions. *Am. J. Med.* 1986, 80, 126–137. [CrossRef]

43. Chumbita, M.; Puerta-Alcalde, P.; Gudiol, C.; Garcia-Pouton, N.; Laporte-Amargós, J.; Ladino, A.; Albasanz-Puig, A.; Helguera, C.; Bergas, A.; Graña, I.; et al. Impact of empirical antibiotic regimens on mortality in neutropenic patients with bloodstream infection presenting with septic shock. *Antimicrob. Agents Chemother.* 2021, 66, AAC-01744. [CrossRef]

44. Criscuolo, M.; Trecarichi, E.M. Ceftazidime/avibactam and ceftolozane/tazobactam for multidrug-resistant gram negatives in patients with hematological malignancies: Current experiences. *Antibiotics* 2020, 9, 58. [CrossRef]

45. Fernández-Cruz, A.; Alba, N.; Semiglia-Chong, M.A.; Padilla, B.; Rodriguez-Macias, G.; Kwon, M.; Cercenado, E.; Chamorro-de-Vega, E.; Machado, M.; Pérez-Lago, L.; et al. A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and pseudomonas aeruginosa infection. *Antimicrob. Agents Chemother.* 2019, 63, e02340-18. [CrossRef]